ArticleBiomaterials2017
Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.
Article in Biomaterials, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Recent advances in nanotherapeutics for HIV-associated neurocognitive disorders and substance use disorders.Nanomedicine (London, England) · 2025Review
- The immunological and pharmacokinetic evaluation of Lipid-PLGA hybrid nanoparticle-based oxycodone vaccines.Biomaterials · 2025Article
- Conjugation of Multiple Proteins Onto the Surface of PLGA/Lipid Hybrid Nanoparticles.Journal of biomedical materials research. Part A · 2025Article
- Vaccines to Treat Substance Use Disorders: Current Status and Future Directions.Pharmaceutics · 2024Review
- Immunotherapies for the Treatment of Drug Addiction.Vaccines · 2022Review
- Nanoparticle delivery systems for substance use disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Review
- Formulation of Nanovaccines toward an Extended Immunity against Nicotine.ACS applied materials & interfaces · 2021Article
- Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Modulation of immune responses using adjuvants to facilitate therapeutic vaccination.Immunological reviews · 2020Review
- Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE.Drug and alcohol dependence · 2019Article
- Modulating Linker Composition of Haptens Resulted in Improved Immunoassay for Histamine.Biomolecules · 2019Article
- Alum as an adjuvant for nanoparticle based vaccines: A case study with a hybrid nanoparticle-based nicotine vaccine.Nanomedicine : nanotechnology, biology, and medicine · 2019Article
- Effect of Adjuvant Release Rate on the Immunogenicity of Nanoparticle-Based Vaccines: A Case Study with a Nanoparticle-Based Nicotine Vaccine.Molecular pharmaceutics · 2019Article
- Paradox of PEGylation in fabricating hybrid nanoparticle-based nicotine vaccines.Biomaterials · 2018Article
- Article
- Hybrid nanoparticle-based nicotine nanovaccines: Boosting the immunological efficacy by conjugation of potent carrier proteins.Nanomedicine : nanotechnology, biology, and medicine · 2018Article
- Drug Delivery Systems from Self-Assembly of Dendron-Polymer ConjugatesMolecules (Basel, Switzerland) · 2018Review
- Design, Synthesis and Architectures of Hybrid Nanomaterials for Therapy and Diagnosis Applications.Polymers · 2018Review
- Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction.Biomaterials · 2018Article
- Rationalization of a nanoparticle-based nicotine nanovaccine as an effective next-generation nicotine vaccine: A focus on hapten localization.Biomaterials · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Although vaccination is a promising way to combat nicotine addiction, most traditional hapten-protein conjugate nicotine vaccines only show limited efficacy due to their poor recognition and uptake by immune cells. This study aimed to develop a hybrid nanoparticle-based nicotine vaccine with improved efficacy. The focus was to study the impact of hapten density on the immunological efficacy of the proposed hybrid nanovaccine. It was shown that the nanovaccine nanoparticles were taken up by the dendritic cells more efficiently than the conjugate vaccine, regardless of the hapten density on the nanoparticles. At a similar hapten density, the nanovaccine induced a significantly stronger immune response against nicotine than the conjugate vaccine in mice. Moreover, the high- and medium-density nanovaccines resulted in significantly higher anti-nicotine antibody titers than their low-density counterpart. Specifically, the high-density nanovaccine exhibited better immunogenic efficacy, resulting in higher anti-nicotine antibody titers and lower anti-carrier protein antibody titers than the medium- and low-density versions. The high-density nanovaccine also had the best ability to retain nicotine in serum and to block nicotine from entering the brain. These results suggest that the hybrid nanoparticle-based nicotine vaccine can elicit strong immunogenicity by modulating the hapten density, thereby providing a promising next-generation immunotherapeutic strategy against nicotine addiction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.